Comparative Analysis of Dexmedetomidine and Dexamethasone as Add-Ons to 0.5% Ropivacaine for Ultrasound-Guided Supraclavicular Brachial Plexus Block in Upper Limb Surgeries

What this Trial Is About

Researchers are comparing the effects of dexmedetomidine and dexamethasone when added to 0.5% ropivacaine for ultrasound-guided supraclavicular brachial plexus block in patients having upper limb surgeries. This study focuses on improving anesthesia onset and postoperative pain relief for surgeries below the mid-humerus level. The trial is a randomized, double-blind study conducted during phases 2 and 3 to assess these two drug combinations. Participants will be randomly assigned to one of two groups: one group receives 28 ml of 0.5% ropivacaine combined with 1 mcg/kg dexmedetomidine diluted in 2 ml normal saline, while the other group receives 28 ml of 0.5% ropivacaine plus 8 mg dexamethasone. The supraclavicular brachial plexus block is performed under ultrasound guidance with the patient lying supine and the head turned 30 degrees away. The drugs are injected carefully around the brachial plexus to ensure effective anesthesia. During the study, patients will be monitored with standard equipment like pulse oximetry, ECG, and blood pressure measurements. Sensory and motor block onset will be checked every 5 minutes up to 30 minutes using standardized scales. Side effects and any complications will be tracked and treated as needed. The primary outcome is the time to onset of sensory and motor block within 5 minutes after block performance. The study is expected to end by March 2026, with participants aged 18 to 70 years included.

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries